An Open, Single Center Trial to Evaluate the Efficacy and Safety of Dose Escalation of Icotinib in Advanced NSCLC Patients After TKI Therapy
Phase of Trial: Phase II
Latest Information Update: 10 May 2017
Price : $35 *
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 03 May 2017 Planned End Date changed from 1 Oct 2014 to 1 Dec 2019.
- 03 May 2017 Planned primary completion date changed from 1 Jul 2014 to 1 Dec 2018.
- 03 May 2017 Status changed from not yet recruiting to recruiting.